Updated:
Vifor Pharma Management Ltd.
Vifor Pharma Management Ltd. is the Swiss family office managing the fortune from the 2022 sale of Vifor Pharma to CSL for $11.7 billion.
Vifor Pharma Management Ltd.
Vifor Pharma Management Ltd. serves as the investment vehicle for the founding family of Vifor Pharma, a Swiss pharmaceutical company established in 1969. The firm was created after the 2022 sale of Vifor Pharma to CSL Limited for approximately $11.7 billion, converting a majority stake into cash and CSL shares. The family office operates from Switzerland, with no public disclosure of its exact founding year or principals. The office pursues a multi-asset strategy, targeting healthcare, life sciences, private equity, and real estate. It makes both direct investments and co-investments alongside external partners. Specific portfolio companies and deal names are not publicly disclosed, making the exact investment footprint difficult to track. The office likely holds significant exposure to CSL shares and has reinvested proceeds into Swiss and international assets. The size of the team and AUM are not publicly disclosed. Given the $11.7 billion exit, estimates suggest a multibillion-dollar asset base — but exact figures remain private. The office maintains a low public profile, with no additional offices confirmed. Philanthropic structures may exist separately but are not linked to the management entity. A structural differentiator is the complete liquidity event that seeded the office: the sale of a private operating company built over generations, converting concentrated operating wealth into a diversified portfolio managed from the same Swiss jurisdiction. The office's governance likely mirrors the family's long-term ownership horizon and conservative investment temperament typical of European pharmaceutical fortunes.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
—
Corporate office
Switzerland
Sector focus
Frequently asked questions
Who runs investment decisions at Vifor Pharma Management Ltd.?
The principals and investment team are not publicly disclosed. As a family office with a low public profile, its governance likely involves the founders' family members and a small team of Swiss-based professionals. No named CIO or CEO has been identified in public records (per public record).
How does Vifor Pharma Management Ltd. source proprietary deal flow?
The office likely benefits from the family's longstanding relationships in the pharmaceutical and life sciences industries. Given its Swiss base, it may also access deal flow through Swiss private equity and real estate networks. However, no specific sourcing mechanisms are publicly documented.
Is Vifor Pharma Management Ltd. structured as a single family office or does it operate more like a venture firm?
It is structured as a single family office, created to manage the wealth of the founding family of Vifor Pharma. It does not appear to operate as a venture firm or external investment manager, maintaining a private governance structure (per public record).
Does Vifor Pharma Management Ltd. participate in fund commitments or only direct deals?
The office appears to make both direct investments and co-investments, though specific fund commitments are not confirmed. Its multi-asset strategy likely includes direct private equity and real estate acquisitions, as well as holdings in public equities like CSL shares (per public record).
What investment stages does Vifor Pharma Management Ltd. typically target?
The office invests across multiple stages, likely including growth equity, buyouts, and real estate. Its healthcare focus suggests familiarity with life sciences company investments, but no specific stage preferences have been disclosed (per public record).
Which sectors does Vifor Pharma Management Ltd. explicitly avoid?
No explicit sector exclusions are publicly known. Based on the family's pharmaceutical origin, the office may concentrate on healthcare and related sectors. It is not known to avoid any specific industries, though it likely stays within its expertise (per public record).
Where does the underlying wealth come from?
The wealth originates from Vifor Pharma, a Swiss pharmaceutical company focused on iron-deficiency therapies, founded in 1969. The family sold a majority stake to CSL Limited in 2022 for approximately $11.7 billion, generating the primary liquidity for the family office (per CSL, 2022).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: